NASDAQ · TLSA
Tiziana Life Sciences financials
$0.9537−2.73%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating income | -$21.1M | -$15.8M | -$18.0M | -$14.6M | -$27.4M | -$30.7M | -$9.9M | -$9.9M |
| Net income | -$18.4M | -$11.9M | -$17.7M | -$15.4M | -$23.4M | -$26.1M | -$9.3M | -$7.9M |
| Net margin | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.16 | $-0.11 | $-0.17 | $-0.15 | $-0.24 | $-0.27 | $-0.10 | $-0.06 |
| EBITDA | -$21.1M | -$15.8M | -$18.0M | -$14.6M | -$27.4M | -$30.4M | -$9.9M | -$9.9M |
| Operating cash flow | -$12.8M | -$1.5M | -$15.7M | -$19.6M | -$21.8M | -$11.3M | -$6.8M | -$4.6M |
| Free cash flow | -$12.9M | -$1.5M | -$15.7M | -$19.6M | -$21.8M | -$11.3M | -$6.8M | -$4.6M |
| Diluted shares | 118.3M | 106.7M | 102.5M | 101.5M | 97.9M | 97.3M | 97.3M | 127.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.0M | $3.7M | $1.2M | $18.1M | $42.2M | $65.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $324.0K |
| Total assets | $11.5M | $11.3M | $12.2M | $26.5M | $48.8M | $70.7M |
| Total liabilities | $11.4M | $7.3M | $6.6M | $6.9M | $7.5M | $8.3M |
| Shareholders' equity | $52.0K | $3.9M | $5.5M | $19.6M | $41.3M | $62.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology